Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + FOLFIRI-3
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Bevacizumab + FOLFIRI-3 is a combination chemotherapy and targeted therapy regimen primarily used in the treatment of metastatic colorectal cancer, especially after failure of standard first-line therapies. The regimen consists of three chemotherapeutic agents—fluorouracil (5-FU), leucovorin calcium (folinic acid), and irinotecan hydrochloride—combined with the monoclonal antibody bevacizumab. Fluorouracil is a pyrimidine analog that inhibits DNA synthesis; leucovorin enhances its efficacy; irinotecan is a topoisomerase I inhibitor that prevents DNA replication; and bevacizumab targets vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis required for tumor growth. This combination has shown activity in patients with metastatic colorectal cancer who have progressed on previous lines of chemotherapy[1][3][5].
- Brand names
- Avastin (for bevacizumab)
- Other names
- fluorouracil + leucovorin calcium + irinotecan hydrochloride + bevacizumab5-FU + folinic acid + irinotecan + bevacizumab
02
Targets
Beyond the preview
Go deeper on bevacizumab + FOLFIRI-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + FOLFIRI-3.